Literature DB >> 19003032

Development of Animal-free, Protein-Free and Chemically-Defined Media for NS0 Cell Culture.

Jinyou Zhang1, David Robinson.   

Abstract

There has been a recent boom of monoclonal antibodies on the market, and a significant portion of them were produced by NS0 cell lines. As regulations become more stringent in ensuring production processes are free of potential contamination by adventitious agents, it is highly desirable to further develop serum-free media into ones that do not contain any components of animal origin, or 'animal-free media'. Using a shake-flask batch culture system, recombinant proteins (human albumin and human insulin) and synthetic compounds (tropolone and ferric ammonium citrate) were identified to be capable of replacing the animal-sourced proteins commonly found in serum-free media for NS0 cell culture, namely bovine albumin, insulin and transferrin. The cholesterol requirement of NS0 cells was satisfied by the use of a commercially available non-proteinaceous, non-animal sourced cholesterol/fatty acid mix in place of bovine lipoproteins, which in effect also eliminated the need for recombinant albumin. In the animal-free medium thus formulated, NS0 cell lines, either the host or recombinant constructs, were all able to grow in batch culture to 1~ 3x10(6) viable cells/ml for multiple passages, with no requirement for gradual adaptation even when seeded from 10% serum-containing cultures. It was surprising to observe that the recombinant insulin was essentially ineffective as sodium salt compared to its zinc salt. Studies showed that the zinc deficiency in the former resulted in a rapid decline of cell viabilities. Supplementation of zinc ions greatly improved growth, and even led to the total replacement of recombinant insulin and hence the formulation of a protein-free medium. When the cell lines were adapted to cholesterol-independent growth which eliminated the need for any lipid source, a completely chemically-defined animal-free medium was formulated. In all cases, antibody production by various GS-NS0 constructs in animal-free media was stable for multiple passages and at least similar to the original serum-free medium containing the animal-sourced proteins. The medium also served well for cryopreservation of NS0 cells in the absence of serum.

Entities:  

Year:  2005        PMID: 19003032      PMCID: PMC3449720          DOI: 10.1007/s10616-005-3563-z

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  32 in total

Review 1.  Safety issues of animal products used in serum-free media.

Authors:  O W Merten
Journal:  Dev Biol Stand       Date:  1999

2.  Growth of NS0 cells in protein-free, chemically defined medium.

Authors:  S Gorfien; B Paul; J Walowitz; R Keem; W Biddle; D Jayme
Journal:  Biotechnol Prog       Date:  2000 Sep-Oct

3.  Adaptation of cholesterol-requiring NS0 mouse myeloma cells to high density growth in a fully defined protein-free and cholesterol-free culture medium.

Authors:  M J Keen; T W Steward
Journal:  Cytotechnology       Date:  1995-10       Impact factor: 2.058

4.  Fed-batch culture of recombinant NS0 myeloma cells with high monoclonal antibody production.

Authors:  W Zhou; C C Chen; B Buckland; J Aunins
Journal:  Biotechnol Bioeng       Date:  1997-09-05       Impact factor: 4.530

5.  Adventitious agents from animal-derived raw materials and production systems.

Authors:  K B Hellman; J P Honstead; C K Vincent
Journal:  Dev Biol Stand       Date:  1996

Review 6.  Cell death (apoptosis) in cell culture systems.

Authors:  T G Cotter; M al-Rubeai
Journal:  Trends Biotechnol       Date:  1995-04       Impact factor: 19.536

7.  Opinion of the EMEA on the potential risk associated with medicinal products in relation to bovine spongiform encephalopathy (BSE) (16 April 1996) and report from the Committee for Proprietary Medicinal Products (CPMP) on the 'Note for Guidance on minimizing the risk of transmitting animal spongiform encephalopathies via medicinal products' (15 April 1997).

Authors: 
Journal:  Adverse Drug React Toxicol Rev       Date:  1997-06

8.  High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker.

Authors:  C R Bebbington; G Renner; S Thomson; D King; D Abrams; G T Yarranton
Journal:  Biotechnology (N Y)       Date:  1992-02

9.  Advances in animal cell recombinant protein production: GS-NS0 expression system.

Authors:  L M Barnes; C M Bentley; A J Dickson
Journal:  Cytotechnology       Date:  2000-02       Impact factor: 2.058

10.  Virus contaminations of cell cultures - A biotechnological view.

Authors:  O-W Merten
Journal:  Cytotechnology       Date:  2002-07       Impact factor: 2.058

View more
  8 in total

1.  The role of recombinant proteins in the development of serum-free media.

Authors:  Joanne Keenan; Dermot Pearson; Martin Clynes
Journal:  Cytotechnology       Date:  2006-08-05       Impact factor: 2.058

Review 2.  Recombinant organisms for production of industrial products.

Authors:  Jose-Luis Adrio; Arnold L Demain
Journal:  Bioeng Bugs       Date:  2009-11-02

3.  Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody.

Authors:  Shui-On Leung; Kai Gao; Guang Yu Wang; Benny Ka-Wa Cheung; Kwan-Yeung Lee; Qi Zhao; Wing-Tai Cheung; Jun Zhi Wang
Journal:  MAbs       Date:  2015       Impact factor: 5.857

4.  Rational development of a serum-free medium and fed-batch process for a GS-CHO cell line expressing recombinant antibody.

Authors:  Huifeng Zhang; Haibin Wang; Mei Liu; Tao Zhang; Ji Zhang; Xiangjing Wang; Wensheng Xiang
Journal:  Cytotechnology       Date:  2012-08-21       Impact factor: 2.058

5.  Characterization of mammalian cell culture raw materials by combining spectroscopy and chemometrics.

Authors:  Nicholas Trunfio; Haewoo Lee; Jason Starkey; Cyrus Agarabi; Jay Liu; Seongkyu Yoon
Journal:  Biotechnol Prog       Date:  2017-05-16

6.  Safety risk management for low molecular weight process-related impurities in monoclonal antibody therapeutics: Categorization, risk assessment, testing strategy, and process development with leveraging clearance potential.

Authors:  Haibin Luo; Yuling Li; David Robbins; Sheau-Chiann Wang; Guoling Xi; Matthew Cox; Simone M Nicholson; Chenghong Wei; Timothy M Pabst; William K Wang
Journal:  Biotechnol Prog       Date:  2021-01-06

Review 7.  Purification of Capsular Polysaccharides of Streptococcus pneumoniae: Traditional and New Methods.

Authors:  Victor Morais; Valerie Dee; Norma Suárez
Journal:  Front Bioeng Biotechnol       Date:  2018-10-12

Review 8.  Systems for Muscle Cell Differentiation: From Bioengineering to Future Food.

Authors:  Kah-Yin Lee; Hui-Xin Loh; Andrew C A Wan
Journal:  Micromachines (Basel)       Date:  2021-12-31       Impact factor: 2.891

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.